Complete remission treated by Bcl-2 inhibitor combined with Blinatumomab as induction treatment for adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation: A multicenter, prospective, randomized controlled, open-label, phase II study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: b5f8d12aa8683a2106eb0b2cedb7c3bdbd4416a2
First added on: Apr 24, 2026